Genethon and Eukarÿs announce a strategic partnership to develop a breakthrough technology to reduce the biomanufacturing cost of gene therapies

Strategic Partnership Overview - Genethon and Eukarÿs announced a strategic partnership to reduce the biomanufacturing cost of gene therapies by leveraging Eukarÿs' proprietary C3P3 technology [1] - The collaboration aims to improve the production of AAV vectors, a key delivery method for therapeutic genes [3] - Genethon will contribute its expertise in AAV vector design and production, while Eukarÿs will provide its patented C3P3 technology [4] Industry Context - Gene therapies offer significant potential for treating rare and common diseases, but high biomanufacturing costs remain a major barrier to their development and commercialization [2] - Improving production technologies and increasing biomanufacturing yields are critical to making these therapies more accessible [2] Technology Innovation - Eukarÿs' C3P3 enzyme enhances mRNA synthesis capabilities in mammalian cells, increasing production yields by 5 to 7 times [6] - The C3P3 technology is universal, requiring no adaptation for most biopharmaceuticals, and can be integrated into existing industrial processes without additional investment [6] - The enzyme is suitable for producing a wide range of biopharmaceuticals, including monoclonal antibodies, recombinant proteins, and Virus-like particles (VLPs) [6] Company Profiles - Genethon is a non-profit organization specializing in gene therapy development for rare diseases, with 13 products in clinical trials and 7 more expected to enter trials in the next five years [7] - Eukarÿs, founded in 2010, has developed the C3P3 technology to transform biopharmaceutical production and has received significant recognition, including the Sanofi Golden Ticket in 2024 [8][9] Leadership Perspectives - Patrick Santambien of Genethon highlighted the disruptive potential of Eukarÿs' technology in reducing biomanufacturing costs and improving AAV vector production [5] - Guillaume Prunier, CEO of Eukarÿs, emphasized the importance of the partnership in accelerating the adaptation of C3P3 for gene therapy, particularly for AAV and lentiviruses [5]